Daniel Pollyea
Concepts (487)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 121 | 2026 | 700 | 26.590 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 45 | 2026 | 291 | 11.000 |
Why?
| | Sulfonamides | 45 | 2026 | 592 | 9.650 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 54 | 2026 | 1996 | 8.180 |
Why?
| | Myelodysplastic Syndromes | 31 | 2026 | 170 | 6.850 |
Why?
| | Azacitidine | 25 | 2026 | 168 | 6.450 |
Why?
| | Antineoplastic Agents | 26 | 2026 | 2218 | 3.380 |
Why?
| | Mutation | 37 | 2026 | 4082 | 2.990 |
Why?
| | Isocitrate Dehydrogenase | 13 | 2022 | 71 | 2.750 |
Why?
| | Hematologic Neoplasms | 10 | 2023 | 169 | 2.590 |
Why?
| | Neoplasm, Residual | 8 | 2026 | 143 | 2.360 |
Why?
| | Neoplastic Stem Cells | 15 | 2025 | 402 | 2.290 |
Why?
| | Hematopoietic Stem Cell Transplantation | 17 | 2024 | 700 | 2.070 |
Why?
| | Triazines | 7 | 2021 | 48 | 1.820 |
Why?
| | Aminopyridines | 7 | 2021 | 128 | 1.750 |
Why?
| | Remission Induction | 16 | 2026 | 308 | 1.640 |
Why?
| | Prognosis | 31 | 2026 | 4331 | 1.580 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2025 | 1156 | 1.570 |
Why?
| | Graft vs Host Disease | 9 | 2024 | 280 | 1.550 |
Why?
| | Humans | 169 | 2026 | 145625 | 1.370 |
Why?
| | RNA Splicing Factors | 3 | 2020 | 66 | 1.340 |
Why?
| | Aged | 65 | 2026 | 26251 | 1.330 |
Why?
| | Aged, 80 and over | 35 | 2026 | 8351 | 1.310 |
Why?
| | Treatment Outcome | 37 | 2026 | 11744 | 1.200 |
Why?
| | Phosphoproteins | 3 | 2020 | 319 | 1.180 |
Why?
| | Cytarabine | 8 | 2022 | 66 | 1.150 |
Why?
| | Leukemia | 4 | 2023 | 246 | 1.040 |
Why?
| | Middle Aged | 54 | 2026 | 36359 | 0.960 |
Why?
| | Salvage Therapy | 5 | 2023 | 163 | 0.940 |
Why?
| | Immunotherapy, Adoptive | 3 | 2025 | 356 | 0.930 |
Why?
| | Clonal Evolution | 2 | 2017 | 47 | 0.920 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2025 | 7 | 0.920 |
Why?
| | Cord Blood Stem Cell Transplantation | 4 | 2024 | 103 | 0.900 |
Why?
| | DNA Methylation | 5 | 2026 | 721 | 0.870 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 76 | 0.830 |
Why?
| | fms-Like Tyrosine Kinase 3 | 4 | 2017 | 51 | 0.830 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 299 | 0.810 |
Why?
| | Drug Resistance, Neoplasm | 9 | 2025 | 889 | 0.810 |
Why?
| | Nuclear Proteins | 5 | 2018 | 739 | 0.810 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2025 | 207 | 0.800 |
Why?
| | Molecular Targeted Therapy | 7 | 2024 | 446 | 0.780 |
Why?
| | Carrier Proteins | 3 | 2017 | 728 | 0.770 |
Why?
| | Transplantation Conditioning | 9 | 2024 | 191 | 0.760 |
Why?
| | Leukemia, Neutrophilic, Chronic | 3 | 2019 | 5 | 0.750 |
Why?
| | Male | 64 | 2026 | 73014 | 0.750 |
Why?
| | Female | 69 | 2026 | 79080 | 0.730 |
Why?
| | Thrombocytopenia | 2 | 2023 | 205 | 0.730 |
Why?
| | Spliceosomes | 2 | 2020 | 54 | 0.720 |
Why?
| | Dancing | 1 | 2022 | 19 | 0.720 |
Why?
| | Adult | 40 | 2026 | 40821 | 0.710 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 4 | 2018 | 237 | 0.690 |
Why?
| | Enzyme Inhibitors | 5 | 2020 | 820 | 0.690 |
Why?
| | Anemia | 2 | 2020 | 189 | 0.680 |
Why?
| | Febrile Neutropenia | 1 | 2020 | 6 | 0.660 |
Why?
| | Splicing Factor U2AF | 2 | 2023 | 18 | 0.630 |
Why?
| | Receptors, Colony-Stimulating Factor | 2 | 2017 | 7 | 0.600 |
Why?
| | T-Lymphocytes | 2 | 2025 | 2007 | 0.600 |
Why?
| | Serine-Arginine Splicing Factors | 2 | 2019 | 27 | 0.600 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2025 | 128 | 0.590 |
Why?
| | Phenylurea Compounds | 7 | 2020 | 122 | 0.550 |
Why?
| | Signal Transduction | 11 | 2026 | 5234 | 0.550 |
Why?
| | Staurosporine | 1 | 2017 | 22 | 0.530 |
Why?
| | Stem Cells | 3 | 2020 | 612 | 0.530 |
Why?
| | Benzimidazoles | 6 | 2020 | 189 | 0.500 |
Why?
| | Gene Frequency | 2 | 2017 | 495 | 0.480 |
Why?
| | Protein Kinase Inhibitors | 10 | 2025 | 982 | 0.470 |
Why?
| | Monocytes | 2 | 2018 | 538 | 0.460 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 5 | 0.460 |
Why?
| | Recurrence | 9 | 2023 | 1125 | 0.460 |
Why?
| | Leukocytosis | 1 | 2015 | 31 | 0.460 |
Why?
| | Skin Neoplasms | 1 | 2023 | 805 | 0.460 |
Why?
| | Glycine | 4 | 2021 | 184 | 0.450 |
Why?
| | Gene Expression | 1 | 2020 | 1461 | 0.450 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 538 | 0.450 |
Why?
| | Retrospective Studies | 17 | 2026 | 17291 | 0.420 |
Why?
| | Epigenesis, Genetic | 1 | 2019 | 705 | 0.420 |
Why?
| | Maximum Tolerated Dose | 5 | 2019 | 216 | 0.420 |
Why?
| | Precision Medicine | 1 | 2018 | 462 | 0.410 |
Why?
| | Oxidative Phosphorylation | 6 | 2024 | 212 | 0.410 |
Why?
| | Computational Biology | 1 | 2019 | 675 | 0.410 |
Why?
| | Hematopoietic Stem Cells | 4 | 2026 | 432 | 0.410 |
Why?
| | Patient Safety | 1 | 2018 | 351 | 0.410 |
Why?
| | Young Adult | 17 | 2026 | 14240 | 0.400 |
Why?
| | Clinical Trials, Phase I as Topic | 2 | 2024 | 49 | 0.400 |
Why?
| | Apoptosis | 4 | 2018 | 2436 | 0.400 |
Why?
| | Pyridines | 5 | 2023 | 606 | 0.400 |
Why?
| | Induction Chemotherapy | 3 | 2024 | 87 | 0.400 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2024 | 116 | 0.390 |
Why?
| | Hematopoiesis | 4 | 2020 | 195 | 0.390 |
Why?
| | Medical Oncology | 4 | 2023 | 344 | 0.390 |
Why?
| | Neoplasm Proteins | 4 | 2022 | 443 | 0.390 |
Why?
| | Neoplasms | 5 | 2025 | 2944 | 0.380 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2021 | 2018 | 0.370 |
Why?
| | Immunity, Innate | 1 | 2019 | 843 | 0.370 |
Why?
| | Pyrazoles | 1 | 2017 | 516 | 0.370 |
Why?
| | Germ-Line Mutation | 3 | 2022 | 180 | 0.370 |
Why?
| | Leukemia, Myeloid | 1 | 2012 | 49 | 0.370 |
Why?
| | Mitochondria | 4 | 2025 | 996 | 0.370 |
Why?
| | Glutarates | 1 | 2012 | 11 | 0.370 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 2 | 2018 | 37 | 0.350 |
Why?
| | STAT3 Transcription Factor | 2 | 2025 | 214 | 0.350 |
Why?
| | Biomarkers, Tumor | 5 | 2025 | 1334 | 0.350 |
Why?
| | Survival Rate | 11 | 2025 | 2078 | 0.340 |
Why?
| | RNA Splicing | 4 | 2023 | 287 | 0.330 |
Why?
| | Neutrophils | 2 | 2023 | 1132 | 0.330 |
Why?
| | United States Food and Drug Administration | 2 | 2022 | 207 | 0.330 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 377 | 0.320 |
Why?
| | Follow-Up Studies | 8 | 2020 | 5397 | 0.320 |
Why?
| | Cytokines | 5 | 2026 | 2079 | 0.320 |
Why?
| | Aldehyde Dehydrogenase | 3 | 2017 | 98 | 0.320 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2023 | 992 | 0.310 |
Why?
| | Leukocyte Count | 2 | 2024 | 319 | 0.310 |
Why?
| | Rhipicephalus sanguineus | 1 | 2009 | 1 | 0.310 |
Why?
| | Triatoma | 1 | 2009 | 7 | 0.310 |
Why?
| | Insect Bites and Stings | 1 | 2009 | 13 | 0.310 |
Why?
| | Risk Assessment | 6 | 2026 | 3678 | 0.300 |
Why?
| | Wasps | 1 | 2009 | 23 | 0.300 |
Why?
| | Syncope | 1 | 2009 | 48 | 0.300 |
Why?
| | Electron Transport Complex II | 2 | 2019 | 27 | 0.290 |
Why?
| | Mutant Proteins | 2 | 2019 | 103 | 0.280 |
Why?
| | Kaplan-Meier Estimate | 5 | 2020 | 959 | 0.280 |
Why?
| | Proto-Oncogene Proteins | 2 | 2018 | 615 | 0.280 |
Why?
| | Cell Self Renewal | 2 | 2019 | 50 | 0.280 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 161 | 0.280 |
Why?
| | Anaphylaxis | 1 | 2009 | 105 | 0.270 |
Why?
| | Acute Disease | 3 | 2023 | 1033 | 0.270 |
Why?
| | Administration, Oral | 4 | 2018 | 867 | 0.270 |
Why?
| | Bone Marrow | 4 | 2017 | 308 | 0.270 |
Why?
| | Transplantation, Homologous | 6 | 2022 | 415 | 0.260 |
Why?
| | Niacinamide | 2 | 2026 | 103 | 0.260 |
Why?
| | Animals | 29 | 2026 | 38030 | 0.260 |
Why?
| | Survival Analysis | 6 | 2020 | 1372 | 0.260 |
Why?
| | Gene Expression Regulation, Leukemic | 3 | 2016 | 56 | 0.260 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2024 | 1754 | 0.260 |
Why?
| | Drug Administration Schedule | 4 | 2020 | 782 | 0.250 |
Why?
| | Disease-Free Survival | 5 | 2022 | 777 | 0.250 |
Why?
| | Sarcoma, Myeloid | 1 | 2026 | 6 | 0.240 |
Why?
| | Mice | 20 | 2026 | 18266 | 0.240 |
Why?
| | Primary Myelofibrosis | 2 | 2016 | 8 | 0.240 |
Why?
| | Thrombocythemia, Essential | 2 | 2016 | 7 | 0.240 |
Why?
| | Polycythemia Vera | 2 | 2016 | 9 | 0.230 |
Why?
| | Cytogenetic Analysis | 2 | 2022 | 34 | 0.230 |
Why?
| | ras Proteins | 1 | 2026 | 148 | 0.220 |
Why?
| | Voltage-Dependent Anion Channel 1 | 1 | 2025 | 15 | 0.220 |
Why?
| | Hematopoietic Cell Growth Factors | 1 | 2025 | 5 | 0.220 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 1062 | 0.220 |
Why?
| | Phenotype | 3 | 2025 | 3186 | 0.220 |
Why?
| | Influenza Vaccines | 1 | 2010 | 541 | 0.220 |
Why?
| | DEAD-box RNA Helicases | 2 | 2015 | 89 | 0.210 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 23 | 0.210 |
Why?
| | Tumor Microenvironment | 2 | 2026 | 745 | 0.200 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2025 | 158 | 0.200 |
Why?
| | Stem Cell Transplantation | 3 | 2023 | 189 | 0.200 |
Why?
| | Influenza, Human | 1 | 2010 | 634 | 0.200 |
Why?
| | Azetidines | 1 | 2024 | 45 | 0.200 |
Why?
| | Allografts | 2 | 2021 | 148 | 0.200 |
Why?
| | Finland | 1 | 2023 | 72 | 0.190 |
Why?
| | DNA Mutational Analysis | 4 | 2019 | 409 | 0.190 |
Why?
| | Down-Regulation | 1 | 2025 | 612 | 0.190 |
Why?
| | DNA-Binding Proteins | 1 | 2010 | 1467 | 0.190 |
Why?
| | Drug Therapy, Combination | 4 | 2022 | 1034 | 0.190 |
Why?
| | Time-to-Treatment | 1 | 2025 | 257 | 0.190 |
Why?
| | Antibodies, Neoplasm | 3 | 2007 | 34 | 0.190 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1511 | 0.190 |
Why?
| | Disease Management | 4 | 2021 | 649 | 0.190 |
Why?
| | Uncertainty | 1 | 2023 | 145 | 0.180 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 2 | 2019 | 17 | 0.180 |
Why?
| | RNA, Messenger | 1 | 2010 | 2783 | 0.180 |
Why?
| | Piperidines | 1 | 2024 | 223 | 0.180 |
Why?
| | Myeloproliferative Disorders | 1 | 2022 | 21 | 0.180 |
Why?
| | Hematology | 1 | 2022 | 21 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2022 | 157 | 0.180 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 12 | 0.180 |
Why?
| | Thalidomide | 2 | 2012 | 43 | 0.180 |
Why?
| | Succinate Dehydrogenase | 2 | 2019 | 65 | 0.170 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 47 | 0.170 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2023 | 124 | 0.170 |
Why?
| | Calcium | 2 | 2025 | 1181 | 0.170 |
Why?
| | Disease Progression | 3 | 2023 | 2857 | 0.170 |
Why?
| | Receptors, Mitogen | 1 | 2021 | 7 | 0.170 |
Why?
| | Cell Line, Tumor | 8 | 2025 | 3538 | 0.170 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1030 | 0.170 |
Why?
| | Lectins, C-Type | 1 | 2021 | 61 | 0.160 |
Why?
| | Blood Cell Count | 1 | 2020 | 56 | 0.160 |
Why?
| | Erythroblasts | 1 | 2020 | 18 | 0.160 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 314 | 0.160 |
Why?
| | Lipids | 1 | 2025 | 715 | 0.160 |
Why?
| | Inflammation Mediators | 2 | 2020 | 507 | 0.160 |
Why?
| | Histocompatibility Testing | 2 | 2019 | 122 | 0.150 |
Why?
| | Lipase | 1 | 2020 | 76 | 0.150 |
Why?
| | Tumor Lysis Syndrome | 1 | 2019 | 10 | 0.150 |
Why?
| | United States | 6 | 2025 | 16041 | 0.150 |
Why?
| | Cell Survival | 5 | 2025 | 1102 | 0.150 |
Why?
| | Dendritic Cells | 1 | 2023 | 507 | 0.150 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2021 | 138 | 0.150 |
Why?
| | Leukopoiesis | 1 | 2019 | 11 | 0.150 |
Why?
| | Immunoconjugates | 1 | 2021 | 138 | 0.150 |
Why?
| | NADPH Oxidase 2 | 1 | 2019 | 32 | 0.150 |
Why?
| | Myeloid Progenitor Cells | 1 | 2019 | 16 | 0.150 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2019 | 22 | 0.140 |
Why?
| | Age Factors | 5 | 2022 | 3321 | 0.140 |
Why?
| | K562 Cells | 1 | 2019 | 93 | 0.140 |
Why?
| | RAW 264.7 Cells | 1 | 2019 | 51 | 0.140 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 11 | 0.140 |
Why?
| | Fatty Acids | 2 | 2020 | 460 | 0.140 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 22 | 0.140 |
Why?
| | Genetic Testing | 2 | 2019 | 491 | 0.140 |
Why?
| | Mycoses | 1 | 2019 | 86 | 0.140 |
Why?
| | Hematologic Diseases | 1 | 2019 | 66 | 0.140 |
Why?
| | Antibodies | 1 | 2021 | 395 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 530 | 0.140 |
Why?
| | Mitochondrial Proteins | 2 | 2018 | 263 | 0.140 |
Why?
| | Genomics | 3 | 2019 | 851 | 0.140 |
Why?
| | Thiotepa | 1 | 2018 | 21 | 0.140 |
Why?
| | Trees | 1 | 2018 | 60 | 0.140 |
Why?
| | Amino Acids | 2 | 2020 | 513 | 0.140 |
Why?
| | Antibiotic Prophylaxis | 1 | 2019 | 133 | 0.140 |
Why?
| | Macrophages | 1 | 2026 | 1530 | 0.140 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 108 | 0.140 |
Why?
| | Cysteine | 1 | 2019 | 210 | 0.130 |
Why?
| | Lymphoma | 2 | 2017 | 251 | 0.130 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 68 | 0.130 |
Why?
| | HLA-DR Antigens | 1 | 2018 | 211 | 0.130 |
Why?
| | Confidence Intervals | 1 | 2018 | 328 | 0.130 |
Why?
| | Hematinics | 1 | 2017 | 22 | 0.120 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 54 | 0.120 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2018 | 192 | 0.120 |
Why?
| | Infusions, Intravenous | 1 | 2018 | 429 | 0.120 |
Why?
| | Hedgehog Proteins | 1 | 2018 | 194 | 0.120 |
Why?
| | Periodicals as Topic | 1 | 2019 | 209 | 0.120 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 69 | 0.120 |
Why?
| | Unrelated Donors | 1 | 2016 | 39 | 0.120 |
Why?
| | Registries | 3 | 2025 | 2382 | 0.120 |
Why?
| | Genome, Human | 1 | 2018 | 425 | 0.120 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 70 | 0.120 |
Why?
| | Cohort Studies | 5 | 2022 | 6045 | 0.120 |
Why?
| | Pyrimidines | 2 | 2017 | 530 | 0.120 |
Why?
| | Energy Metabolism | 2 | 2019 | 930 | 0.110 |
Why?
| | Geriatric Assessment | 1 | 2018 | 238 | 0.110 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2016 | 96 | 0.110 |
Why?
| | Oncogene Proteins | 1 | 2016 | 61 | 0.110 |
Why?
| | Nitriles | 1 | 2017 | 211 | 0.110 |
Why?
| | Mice, Inbred NOD | 4 | 2019 | 598 | 0.110 |
Why?
| | Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 13 | 0.110 |
Why?
| | Methyltransferases | 1 | 2016 | 73 | 0.110 |
Why?
| | Lipopolysaccharides | 1 | 2019 | 861 | 0.110 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 72 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2022 | 2455 | 0.110 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 268 | 0.110 |
Why?
| | Oligomycins | 1 | 2014 | 7 | 0.110 |
Why?
| | Biomarkers | 3 | 2022 | 4329 | 0.110 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 167 | 0.110 |
Why?
| | Hemoglobins | 2 | 2018 | 384 | 0.110 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 23 | 0.110 |
Why?
| | Adolescent | 7 | 2024 | 22451 | 0.110 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 333 | 0.100 |
Why?
| | Homeostasis | 1 | 2018 | 646 | 0.100 |
Why?
| | Electronic Health Records | 1 | 2023 | 1208 | 0.100 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 67 | 0.100 |
Why?
| | Necrosis | 1 | 2015 | 243 | 0.100 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2016 | 141 | 0.100 |
Why?
| | Cells, Cultured | 5 | 2019 | 4112 | 0.100 |
Why?
| | Vidarabine | 2 | 2018 | 32 | 0.100 |
Why?
| | Harringtonines | 1 | 2013 | 2 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 314 | 0.100 |
Why?
| | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2013 | 1 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2097 | 0.100 |
Why?
| | Alemtuzumab | 3 | 2007 | 15 | 0.100 |
Why?
| | Interleukin-1 | 1 | 2017 | 960 | 0.100 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1790 | 0.090 |
Why?
| | Glucose | 1 | 2018 | 1051 | 0.090 |
Why?
| | Pyridazines | 1 | 2013 | 56 | 0.090 |
Why?
| | Carbon Monoxide | 1 | 2013 | 82 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1429 | 0.090 |
Why?
| | Nausea | 1 | 2012 | 111 | 0.090 |
Why?
| | 5-Methylcytosine | 1 | 2012 | 24 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1073 | 0.090 |
Why?
| | Vomiting | 1 | 2012 | 131 | 0.090 |
Why?
| | Liver | 1 | 2020 | 1859 | 0.090 |
Why?
| | Membrane Proteins | 1 | 2018 | 1130 | 0.090 |
Why?
| | Imidazoles | 1 | 2013 | 244 | 0.090 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 2 | 2023 | 32 | 0.080 |
Why?
| | Incidence | 2 | 2016 | 2910 | 0.080 |
Why?
| | Amino Acid Sequence | 2 | 2015 | 2088 | 0.080 |
Why?
| | Sesquiterpenes | 2 | 2016 | 51 | 0.080 |
Why?
| | Oxidants | 1 | 2011 | 100 | 0.080 |
Why?
| | Dioxygenases | 1 | 2010 | 36 | 0.080 |
Why?
| | Software | 1 | 2015 | 673 | 0.080 |
Why?
| | Fatigue | 1 | 2012 | 362 | 0.080 |
Why?
| | GTP-Binding Proteins | 1 | 2011 | 150 | 0.080 |
Why?
| | Length of Stay | 1 | 2016 | 1342 | 0.080 |
Why?
| | Chronic Disease | 1 | 2016 | 1824 | 0.080 |
Why?
| | Wasp Venoms | 1 | 2009 | 4 | 0.080 |
Why?
| | Ethanol | 1 | 2015 | 629 | 0.080 |
Why?
| | Insulin Resistance | 1 | 2018 | 1247 | 0.080 |
Why?
| | Protein Multimerization | 1 | 2011 | 201 | 0.070 |
Why?
| | Blast Crisis | 2 | 2025 | 34 | 0.070 |
Why?
| | Injections, Subcutaneous | 1 | 2009 | 170 | 0.070 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 337 | 0.070 |
Why?
| | Mice, Transgenic | 3 | 2023 | 2131 | 0.070 |
Why?
| | Epinephrine | 1 | 2009 | 160 | 0.070 |
Why?
| | Immunization Schedule | 1 | 2010 | 186 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 243 | 0.070 |
Why?
| | Emergencies | 1 | 2009 | 173 | 0.070 |
Why?
| | RNA, Small Interfering | 3 | 2016 | 630 | 0.070 |
Why?
| | Melphalan | 1 | 2007 | 43 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2915 | 0.060 |
Why?
| | Phosphorylation | 2 | 2025 | 1717 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 2022 | 878 | 0.060 |
Why?
| | Transplantation Chimera | 1 | 2007 | 57 | 0.060 |
Why?
| | Blood Transfusion | 2 | 2020 | 393 | 0.060 |
Why?
| | Karnofsky Performance Status | 1 | 2006 | 37 | 0.060 |
Why?
| | Nicotinamide Phosphoribosyltransferase | 1 | 2026 | 26 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2026 | 1979 | 0.060 |
Why?
| | HEK293 Cells | 2 | 2019 | 746 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2026 | 4565 | 0.060 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2014 | 429 | 0.060 |
Why?
| | Receptors, Thrombopoietin | 2 | 2016 | 6 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2020 | 6021 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 727 | 0.060 |
Why?
| | Calreticulin | 2 | 2016 | 22 | 0.060 |
Why?
| | Janus Kinase 2 | 2 | 2016 | 31 | 0.060 |
Why?
| | Exome | 2 | 2018 | 232 | 0.060 |
Why?
| | Ganciclovir | 1 | 2006 | 51 | 0.060 |
Why?
| | Valine | 1 | 2006 | 84 | 0.060 |
Why?
| | Acyclovir | 1 | 2006 | 97 | 0.060 |
Why?
| | Philadelphia Chromosome | 2 | 2016 | 18 | 0.050 |
Why?
| | Cell Proliferation | 3 | 2020 | 2497 | 0.050 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2025 | 90 | 0.050 |
Why?
| | Risk Factors | 3 | 2014 | 10840 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 298 | 0.050 |
Why?
| | Phagocytosis | 1 | 2026 | 298 | 0.050 |
Why?
| | Pedigree | 2 | 2015 | 507 | 0.050 |
Why?
| | Janus Kinases | 2 | 2015 | 21 | 0.050 |
Why?
| | Oxidation-Reduction | 2 | 2019 | 1075 | 0.050 |
Why?
| | Cytomegalovirus Infections | 1 | 2006 | 203 | 0.050 |
Why?
| | Diamines | 1 | 2023 | 5 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 89 | 0.050 |
Why?
| | para-Aminobenzoates | 1 | 2023 | 8 | 0.050 |
Why?
| | Chemotaxis | 1 | 2023 | 121 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2016 | 928 | 0.050 |
Why?
| | Flow Cytometry | 2 | 2018 | 1160 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2023 | 120 | 0.050 |
Why?
| | Angiogenesis Inhibitors | 1 | 2004 | 238 | 0.040 |
Why?
| | Pyrrolidines | 1 | 2023 | 126 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2015 | 2411 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1581 | 0.040 |
Why?
| | Neutropenia | 1 | 2022 | 153 | 0.040 |
Why?
| | Drug Interactions | 2 | 2013 | 403 | 0.040 |
Why?
| | Benzodiazepines | 1 | 2023 | 156 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2025 | 1361 | 0.040 |
Why?
| | Early Termination of Clinical Trials | 1 | 2021 | 18 | 0.040 |
Why?
| | Quinuclidines | 1 | 2020 | 11 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2020 | 74 | 0.040 |
Why?
| | Hyperbilirubinemia | 1 | 2020 | 11 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2022 | 371 | 0.040 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 103 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2006 | 774 | 0.040 |
Why?
| | Machine Learning | 1 | 2025 | 590 | 0.040 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1318 | 0.040 |
Why?
| | Lentivirus | 1 | 2019 | 61 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 339 | 0.040 |
Why?
| | Mice, Nude | 2 | 2015 | 665 | 0.040 |
Why?
| | Daunorubicin | 1 | 2018 | 25 | 0.040 |
Why?
| | Consolidation Chemotherapy | 1 | 2018 | 11 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2018 | 41 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2020 | 413 | 0.030 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 23 | 0.030 |
Why?
| | Mice, SCID | 1 | 2019 | 360 | 0.030 |
Why?
| | Datasets as Topic | 1 | 2018 | 120 | 0.030 |
Why?
| | Mice, Knockout | 2 | 2016 | 3121 | 0.030 |
Why?
| | Iron | 1 | 2020 | 359 | 0.030 |
Why?
| | Cause of Death | 1 | 2020 | 455 | 0.030 |
Why?
| | Fetal Blood | 1 | 2020 | 325 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 208 | 0.030 |
Why?
| | Whole-Body Irradiation | 1 | 2018 | 73 | 0.030 |
Why?
| | Cell Count | 1 | 2018 | 315 | 0.030 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 16 | 0.030 |
Why?
| | HLA Antigens | 1 | 2019 | 241 | 0.030 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 200 | 0.030 |
Why?
| | Biological Transport | 1 | 2018 | 423 | 0.030 |
Why?
| | Child | 2 | 2024 | 22638 | 0.030 |
Why?
| | Tumor Stem Cell Assay | 1 | 2017 | 33 | 0.030 |
Why?
| | Glutathione | 1 | 2019 | 369 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 364 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2017 | 27 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1269 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2018 | 267 | 0.030 |
Why?
| | Arsenicals | 1 | 2017 | 28 | 0.030 |
Why?
| | Oxides | 1 | 2017 | 47 | 0.030 |
Why?
| | Glycolysis | 1 | 2018 | 341 | 0.030 |
Why?
| | Benzothiazoles | 1 | 2016 | 39 | 0.030 |
Why?
| | NADP | 1 | 2016 | 52 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 143 | 0.030 |
Why?
| | Hydrazines | 1 | 2016 | 37 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2019 | 494 | 0.030 |
Why?
| | Kinetics | 1 | 2019 | 1553 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2020 | 399 | 0.030 |
Why?
| | Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2016 | 11 | 0.030 |
Why?
| | Deoxyglucose | 1 | 2016 | 51 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 2017 | 275 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 211 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 610 | 0.030 |
Why?
| | Sample Size | 1 | 2016 | 123 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 441 | 0.030 |
Why?
| | Drug Combinations | 1 | 2017 | 399 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2017 | 262 | 0.030 |
Why?
| | Isoenzymes | 1 | 2016 | 294 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 1066 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 342 | 0.030 |
Why?
| | Splenomegaly | 1 | 2015 | 15 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2017 | 372 | 0.030 |
Why?
| | Colorado | 1 | 2025 | 4588 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2017 | 384 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2018 | 428 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Hydroxyurea | 1 | 2015 | 35 | 0.030 |
Why?
| | Comorbidity | 2 | 2013 | 1652 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 390 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 345 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1500 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2017 | 394 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 533 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 74 | 0.030 |
Why?
| | Imatinib Mesylate | 1 | 2014 | 77 | 0.030 |
Why?
| | Sirolimus | 1 | 2016 | 282 | 0.030 |
Why?
| | Immunologic Factors | 1 | 2017 | 244 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 382 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2023 | 1101 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 198 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 58 | 0.030 |
Why?
| | Quality of Life | 2 | 2016 | 3187 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2015 | 561 | 0.030 |
Why?
| | Age of Onset | 1 | 2015 | 557 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2014 | 66 | 0.020 |
Why?
| | Trans-Activators | 1 | 2016 | 371 | 0.020 |
Why?
| | Thiazoles | 1 | 2014 | 139 | 0.020 |
Why?
| | Research Design | 1 | 2020 | 1139 | 0.020 |
Why?
| | Leukemia, Lymphoid | 1 | 2013 | 27 | 0.020 |
Why?
| | Up-Regulation | 1 | 2016 | 840 | 0.020 |
Why?
| | Drug Synergism | 1 | 2014 | 353 | 0.020 |
Why?
| | Cyclosporine | 1 | 2014 | 256 | 0.020 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 78 | 0.020 |
Why?
| | RNA Interference | 1 | 2014 | 470 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2015 | 1244 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2228 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2016 | 525 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2015 | 632 | 0.020 |
Why?
| | Leupeptins | 1 | 2011 | 13 | 0.020 |
Why?
| | HL-60 Cells | 1 | 2011 | 29 | 0.020 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 543 | 0.020 |
Why?
| | Thrombosis | 1 | 2015 | 397 | 0.020 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2011 | 48 | 0.020 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 42 | 0.020 |
Why?
| | Mitoxantrone | 1 | 2010 | 14 | 0.020 |
Why?
| | Free Radical Scavengers | 1 | 2011 | 81 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2015 | 2835 | 0.020 |
Why?
| | Genotype | 1 | 2015 | 1866 | 0.020 |
Why?
| | Etoposide | 1 | 2010 | 169 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2011 | 163 | 0.020 |
Why?
| | Acetylcysteine | 1 | 2011 | 139 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2011 | 369 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 155 | 0.020 |
Why?
| | Prospective Studies | 2 | 2016 | 8087 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1758 | 0.020 |
Why?
| | Treatment Failure | 1 | 2010 | 358 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2852 | 0.020 |
Why?
| | Insulin | 1 | 2018 | 2524 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2011 | 463 | 0.020 |
Why?
| | Nitroimidazoles | 1 | 2004 | 16 | 0.010 |
Why?
| | Cyclohexanes | 1 | 2004 | 21 | 0.010 |
Why?
| | Fluorescein | 1 | 2004 | 23 | 0.010 |
Why?
| | In Situ Nick-End Labeling | 1 | 2004 | 120 | 0.010 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2004 | 43 | 0.010 |
Why?
| | Lectins | 1 | 2004 | 44 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 2004 | 238 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2004 | 317 | 0.010 |
Why?
| | Microcirculation | 1 | 2004 | 142 | 0.010 |
Why?
| | Angiography | 1 | 2004 | 206 | 0.010 |
Why?
| | Capillaries | 1 | 2004 | 123 | 0.010 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2004 | 140 | 0.010 |
Why?
| | Wilms Tumor | 1 | 2004 | 90 | 0.010 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 285 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 543 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1709 | 0.010 |
Why?
| | Hypoxia | 1 | 2004 | 1209 | 0.010 |
Why?
|
|
Pollyea's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|